Cost effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias

American Journal of Cardiology

Volumn 80, Issue 12, 1997, Pages 1551-1557

  Simons, Grant R ^a   Eisenstein, Eric L ^a   Shaw, Leslee J ^a   Mark, Daniel B ^a   Pritchett, Edward L C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; FLECAINIDE; PROPAFENONE; QUINIDINE; SOTALOL;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; FEMALE; HIGH RISK POPULATION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIORITY JOURNAL; QUALITY CONTROL; SUPRAVENTRICULAR TACHYCARDIA; TELEMETRY;

ANTI-ARRHYTHMIA AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; TACHYCARDIA, SUPRAVENTRICULAR;

EID: 0031465587     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00773-X     Document Type: Article

References (81)

1. Kerr WJ, Bender WL. Paroxysmal ventricular fibrillation with cardiac recovery in a case of auricular fibrillation and complete heart-block while under quinidine sulphate therapy. Heart. 9:1922;269-281.
2. Rokseth R, Storstein O. Quinidine therapy of chronic auricular fibrillation the occurrence and mechanism of syncope . Arch Int Med. 3:1963;185-189.
3. Reynolds EW, VanderArk CR. Quinidine syncope and the delayed repolarization syndromes. Mod Concepts Cardiovasc Dis. 45:1976;117-122.
4. Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation. 65:1982;886-894.
5. Ruskin JN, McGovern B, Garan H, DiMarco JP, Kelly E. Antiarrhythmic drugs a possible cause of out-of-hospital arrest . N Engl J Med. 309:1983;1302-1306.
6. McKibbin J, Pocock WA, Barlow JB, Millar RNS, Obel IW. Sotalol, hypokalemia, syncope, and torsades de pointes. Br Heart J. 51:1984;157-162.
7. Preliminary report effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction . N Engl J Med. 321:1989;406-412.
8. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion a meta-analysis of randomized controlled trials . Circulation. 82:1990;1106-1116.
9. Bedell SE, Deitz DC, Leeman D. Incidence and characteristics of preventable iatrogenic cardiac arrests. JAMA. 265:1991;2815-2820.
10. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 327:1992;227-233.
11. Minardo JD, Heger JJ, Miles WM, Zipes DP, Prystówsky EN. Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. N Engl J Med. 319:1988;257-262.
12. Stanton MS, Prystowsky EN, Fineberg NS, Miles WM, Zipes DP, Heger JJ. Arrhythmogenic effects of antiarrhythmic drugs a study of 506 patients treated for ventricular tachycardia or fibrillation . J Am Coll Cardiol. 14:1989;209-215.
13. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol. 72:1993;44A-50A.
14. Prystowsky EN. Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. Clin Cardiol. 17:(suppl. II):1994;II-7-II-10-II.
15. Prystowsky EN, Benson W, Fuster V, Hart RG, Kay GN, Myerburg RJ, Nacarelli GV, Wyse DG. Management of patients with atrial fibrillation. Circulation. 93:1996;1262-1277.
16. Mark DB. Medical economics and health policy issues for interventional cardiology. Topol EJ. Textbook of Interventional Cardiology. Second Edition. 1993;1323-1353 W.B. Saunders, Philadelphia.
17. Krumholz HM, Pasternak RC, Weinstein MC, Friesinger GC, Ridker PM, Tosteson ANA, Goldman L. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med. 327:1992;7-13.
18. National Center for Health Statistics. Vital statistics of the United States, 1992, Vol II. Section 6, Life Tables. Washington: Public Health Service, 1996.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, Cary, NC.
20. Hasselblad V, McCrory D. Meta-analytic tools for medical decision making. Med Dec Making. 15:1995;81-96.
21. Eddy DM, Hasselblad V, Schachter R. Meta-Analysis by the Confidence Profile Method The Statistical Synthesis of Evidence . 1992;Academic Press, Boston.
22. Allen BJ, Brodsky MA, Doria R, Luckett CR, Thomas R, Henry WL. Oral propafenone therapy for patients with paroxysmal supraventricular tachycarrhythmia. Chest. 94:1988;853-854.
23. Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK, Hawkins RW, Pritchett ELC. Prevention of sympromatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. Circulation. 80:1989;1557-1570.
24. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol. 12:1988;1005-1011.
25. Berns E, Rinkenberger RL, Jeang MK, Dougherty AH, Jenkins M, Naccarelli GV. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol. 59:1987;1337-1341.
26. Boissel JP, Wolf E, Gillet J, Soubrane A, Cavallaro A, Mazoyer G. Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J. 2:1981;49-55.
27. Breithardt G, Borggrefe M, Wiebringhaus E, Siepel L. Effect of propafenone in the Wolff-Parkinson-White syndrome electrophysiologic findings and long-term follow-up . Am J Cardiol. 54:1984;29D-39D.
28. Brodsky M, Saini R, Bellinger R, Zoble R, Weiss R, Powers L. Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. Am Heart J. 127:1994;572-577.
29. Capucci A, Boriani G, Rubino I, Della Casa S, Sanguinetti M, Magnani B. A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol. 43:1994;305-313.
30. Cockrell JL, Scheinman MM, Titus C, Helmy I, Langberg JJ, Lee MA, Griffin JC. Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia. Ann Int Med. 114:1991;189-194.
31. Cramer G. Early and late results of conversion of atrial fibrillation with quinidine. Acta Med Scand Suppl. 490:1968;5-102.
32. DeNoojier C, Sparling CM. Quinidine treatment of chronic lone atrial fibrillation. Clin Cardiol. 13:1990;711-714.
33. Epstein M, Jardine RM, Obel IWP. Flecainide acetate in the treatment of resistant supraventricular arrhythmias. S Afr Med J. 74:1988;559-562.
34. Halmos PB. Direct current conversion of atrial fibrillation. Br Heart J. 28:1966;302-308.
35. Hartel G, Louhija A, Konttinen A. Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharm Ther. 15:1974;551-555.
36. Henthorn RW, Waldo AL, Anderson JL, Gilbert EM, Alpert BL, Bhandari AK, Hawkins RW, Pritchett ELC. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. Circulation. 83:1991;119-125.
37. Hillestad L, Bjefkelund C, Dale J, Maltau J, Storstein O. Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. Br Heart J. 33:1971;518-521.
38. Hoff PI, Tronstad A, Olie B, Ohm O-J. Electrophysiologic and clinical effects of flecainide for recurrent paroxysmal supraventricular tachycardia. Am J Cardiol. 62:1988;585-589.
39. Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation prospective comparison of sotalol versus quinidine . J Am Coll Cardiol. 26:1995;852-858.
40. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotatol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 82:1990;1932-1939.
41. Karlson BW, Torstensson I, Abjorn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. Eur Heart J. 9:1988;284-290.
42. Kerr CR, Klein GJ, Axelson JE, Cooper JC. Propafenone for prevention of recurrent atrial fibrillation. Am J Cardiol. 61:1988;914-916.
43. Kerr CR, Prystowsky EN, Smith WM, Cook L, Gallagher JJ. Electrophysiologic effects of disopyramide phosphate in patients with Wolff-Parkinson-White syndrome. Circulation. 65:1982;869-878.
44. Kuhlkamp V, Schmid F, Risler T, Seipel L. Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. Int J Cardiol. 31:1991;65-69.
45. Kumagai K, Gondo N, Matsuo K, Annoura M, Moroe K, Nakashima Y, Hiroki T, Arakawa K. Wavelength index a predictor of the response to disopyramide in paroxysmal lone atrial fibrillation . Cardiology. 85:1994;184-192.
46. Levi GF, Proto C. Combined treatment of atrial fibrillation with quinidine and beta-blockers. Br Heart J. 34:1972;911-914.
47. Martin A, Benbow LJ, Leach C, Bailey RJ. Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and atrial flutter (interim report). Br J Clin Pract Symp Suppl. 44:1986;52-60.
48. Millar RNS. Efficacy of sotalol in controlling reentrant supraventricular tachycardias. Cardiovasc Drugs Ther. 4:1990;625-630.
49. Nakazawa H, Ishikawa N, Noh J, Sugimoto T, Yoshimoto M, Yashiro T, Ozaki O, Ito K. Efficacy of disopyramide in conversion and prophylaxis of post-thyrotoxic atrial fibrillation. Eur J Clin Pharmacol. 40:1991;215-219.
50. Nathan AW, Hellestrand KJ, Bexton RS, Banim SO, Spurrell RAJ, Camm AJ. Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate. Am Heart J. 107:1984;222-228.
51. Normand JP, Legendre M, Kahn JC, Bourdarias JP, Mathivat A. Comparative efficacy of short-acting and long-acting quinidine for maintenance of sinus rhythm after electrical conversion of atrial fibrillation. Br Heart J. 38:1976;381-387.
52. Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Am J Cardiol. 67:1991;713-717.
53. Porterfield JG, Porterfield LM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol. 63:1989;114-117.
54. Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias. Ann Int Med. 114:1991;539-544.
55. Pritchett ELC, DaTorre SD, Platt ML, McCarville SE, Hougham AJ. Flecainide acetate treatment of paroxysmal atrial fibrillation dose-response studies . J Am Coll Cardiol. 17:1991;297-303.
56. Radford MD, Evans DW. Long-term results of DC reversion of atrial fibrillation. Br Heart J. 39:1968;91-96.
57. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 71:1993;558-563.
58. Santinelli V, DePaola M, Turco P, Smimmo D, Chiariello M. Paroxysmal supraventricular tachycardia experience with propafenone . Angiology. 40:1989;563-568.
59. Schenck-Gustafsson K, Jogestrand T, Nordlander R, Dahlqvist R. Effect of quinidine on digoxin concentration in skeletal muscle and serum in patients with atrial fibrillation. N Engl J Med. 305:1981;209-211.
60. Sihm I, Hansen FA, Rasmussen J, Pedersen AK, Thygesen K. Flecainide acetate in atrial flutter and fibrillation. Eur Heart J. 11:1990;145-148.
61. Singh S, Saini RK, DiMarco J, Kluger J, Gold R, Chen Y. Efficacy and safety of sotalol in digitalized patients with chronic atrial fibrillation. Am J Cardiol. 68:1991;1227-1230.
62. Sodermark T, Edhag O, Sjogren A, Jonsson B, Olsson A, Oro L, et al. Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. Br Heart J. 37:1975;486-492.
63. Sonnhag C, Kallryd A, Nylander E, Ryden L. Long-term efficacy of flecainide in paroxysmal atrial fibrillation. Acta Med Scand. 224:1988;563-569.
64. Stern S. Conversion of chronic atrial fibrillation to sinus rhythm with combined propranolol and quinidine treatment. Am Heart J. 74:1967;171-172.
65. Szekely P, Wynne NA, Pearson DT, Batson GA, Sideris DA. Direct current shock and antidysrhythmic drugs. Br Heart J. 32:1970;209-218.
66. Tonet JL, Bernardeau C, Lechat P, Frank R, Touzet I, Fontaine G, Grosgogeat Y. Comparison between the efficacy of amiodarone and quinidine in the treatment of atrial cardiac arrhythmias. Br J Clin Pract Symp Suppl. 44:1988;42-48.
67. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation. 92:1995;2550-2557.
68. Van Wijk LM, Crijns JH, vanGilst WH, Wesseling H, Lie KI. Flecainide acetate in the treatment of supraventricular tachycardias value of programmed electrical stimulation for long-term prognosis . Am Heart J. 117:1989;365-369.
69. Vassiliadis I, Papoutsakis P, Kallikazaros I, Stefanadis C. Propafenone in the prevention of non-ventricular arrhythmias associated with the Wolff-Parkinson-White syndrome. Int J Cardiol. 27:1990;63-70.
70. Visioli O. Combined propranolol and quinidine treatment in cardiac arrhythmias (lett). Am Heart J. 75:1968;719.
71. VanGelder IC, Crijns HJGM, vanGilst WH, van Wijk LM, Harrier HPM, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol. 64:1989;1317-1321.
72. Weiner P, Ganam R, Ganem R, Zidan F, Rabner M. Clinical course of recent-onset atrial fibrillation treated with oral propafenone. Chest. 195:1994;1013-1016.
73. Zehender M, Hohnloser S, Muller B, Meinertz T, Just H. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation results of a comparative study and a 2-year follow-up . J Am Coll Cardiol. 19:1992;1054-1059.
74. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 29:1992;527-532.
75. Oberg KC, O'Toole MF, Gallastegui JL, Bauman JL. "Late" proarrhythmia due to quinidine. Am J Cardiol. 74:1994;192-194.
76. Reiffel JA, Correia J. Structural heart disease its importance in association with antiarrhythmic drug therapy . Clin Cardiol. 17:(Suppl. II):1994;II-3-II-6.
77. Falk RH. Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Int Med. 117:1992;141-150.
78. Goldman L. Cost-effective strategies in cardiology. Braunwald E. Heart Disease. 1992;1694-1707 W. B. Saunders, Philadelphia.
79. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator compared with streptokinase for acute myocardial infarction. N Engl J Med. 332:1995;1418-1424.
80. Kupperman M, Luce BR, McGovern B, Podrid PF, Bigger JT, Ruskin JN. An analysis of the cost effectiveness of the implantable defibrillator. Circulation. 81:1990;91-100.
81. Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NAM, Pauker SG. Cost-effectiveness of the implantable cardioverter-defibrillator effect of improved battery life and comparison with amiodarone therapy . J Am Coll Cardiol. 19:1992;1323-1334.